Trial · NCT02115256
Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline
NCT02115256, Phase 2, Phase 3, Terminated, Yaakov Beilin; results first posted 2017-06-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline. Trials, record NCT02115256. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02115256
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline
- NCT number
- NCT02115256
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 6 participants, actual
- Lead sponsor
- Yaakov Beilin
- Conditions
- External Cephalic Version
- Interventions
- Intravenous Terbutaline, Intravenous Nitroglycerine
- First posted
- 2014-04-16
- Last updated
- 2017-06-14
- Results first posted
- 2017-06-14
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Successful Version of the Fetus Into the Vertex Position | average of 1 hour | Number of participants that had successful version of the fetus into the vertex position. |
| Secondary | Hypotension | average of 1 hour | Number of participants with hypotension |
| Secondary | Need for Cesarean Delivery | average of 1 hour | Number of participants that needed a cesarean delivery |
| Secondary | Tachycardia | average of 1 hour | Number of participants that had tachycardia |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Successful Version of the Fetus Into the Vertex Position | average of 1 hour | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Hypotension | average of 1 hour | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Need for Cesarean Delivery | average of 1 hour | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Tachycardia | average of 1 hour | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Successful Version of the Fetus Into the Vertex Position | Intravenous Terbutaline | 3 | Participants | ||
| Successful Version of the Fetus Into the Vertex Position | Intravenous Nitroglycerine | 0 | Participants | ||
| Hypotension | Intravenous Terbutaline | 2 | Participants | ||
| Hypotension | Intravenous Nitroglycerine | 1 | Participants | ||
| Need for Cesarean Delivery | Intravenous Terbutaline | 0 | Participants | ||
| Need for Cesarean Delivery | Intravenous Nitroglycerine | 0 | Participants | ||
| Tachycardia | Intravenous Terbutaline | 2 | Participants | ||
| Tachycardia | Intravenous Nitroglycerine | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intravenous Terbutaline | 3 | |
| Overall Study | STARTED | Intravenous Nitroglycerine | 3 | |
| Overall Study | COMPLETED | Intravenous Terbutaline | 3 | |
| Overall Study | COMPLETED | Intravenous Nitroglycerine | 2 | |
| Overall Study | NOT COMPLETED | Intravenous Terbutaline | 0 | |
| Overall Study | NOT COMPLETED | Intravenous Nitroglycerine | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intravenous Terbutaline | 0 | 3 |
| Total, all-cause mortality | Intravenous Nitroglycerine | 0 | 2 |
| Total, other adverse events | Intravenous Terbutaline | 0 | 3 |
| Total, other adverse events | Intravenous Nitroglycerine | 0 | 2 |
| Total, serious adverse events | Intravenous Terbutaline | 0 | 3 |
| Total, serious adverse events | Intravenous Nitroglycerine | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Successful Version of the Fetus Into the Vertex Position | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Need for Cesarean Delivery | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Tachycardia | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: deaths from any cause | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Hypotension | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02115256
GET https://conductscience.org/api/trials/v1/NCT02115256/registered